CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
Sym022drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03489369
NCT03489369Phase 1Completed
CompareCT.gov

A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Symphogen A/S·interventional·Posted Apr 5, 2018·Updated Feb 18, 2021

In Brief

A Phase 1 clinical trial evaluating Sym022 for Metastatic Cancer and 2 related conditions. Completed, enrolled 15 participants across 3 sites in 2 countries.

Detailed Summary

This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Cancer, Solid Tumor, Lymphoma
CountriesCanada, United States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 5, 2018
Enrollment StartMay 8, 2018
Primary CompletionJan 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.2 years ago

Interventions

Sym022drug

Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.